Published in NeuroRx on April 01, 2006
Anger Control Training for Youth With Tourette Syndrome | NCT00486551
Subthalamic Stimulation in Tourette's Syndrome (STN-DBSinTS) | NCT02619084
Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA (2010) 3.28
European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry (2010) 1.92
European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry (2011) 1.86
Clinical course of Tourette syndrome. J Psychosom Res (2009) 1.74
Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings. J Neurodev Disord (2012) 1.73
The genetics of child psychiatric disorders: focus on autism and Tourette syndrome. Neuron (2010) 1.57
Randomized trial of behavior therapy for adults with Tourette syndrome. Arch Gen Psychiatry (2012) 1.45
Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology (2007) 1.30
Neurobiological substrates of Tourette's disorder. J Child Adolesc Psychopharmacol (2010) 1.27
Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry (2009) 1.26
Immunopathogenic mechanisms in tourette syndrome: A critical review. Mov Disord (2009) 1.16
Recent advances in Tourette syndrome. Curr Opin Neurol (2011) 1.13
The immunobiology of Tourette's disorder, pediatric autoimmune neuropsychiatric disorders associated with Streptococcus, and related disorders: a way forward. J Child Adolesc Psychopharmacol (2010) 1.13
Systematic review: pharmacological treatment of tic disorders--efficacy of antipsychotic and alpha-2 adrenergic agonist agents. Neurosci Biobehav Rev (2012) 1.08
Prevalence and clinical correlates of tic disorders in a community sample of school-age children. Eur Child Adolesc Psychiatry (2011) 1.01
Defining treatment response in pediatric tic disorders: a signal detection analysis of the Yale Global Tic Severity Scale. J Child Adolesc Psychopharmacol (2011) 1.00
Living with tics: reduced impairment and improved quality of life for youth with chronic tic disorders. Psychiatry Res (2014) 0.95
Update on the role of antipsychotics in the treatment of Tourette syndrome. Neuropsychiatr Dis Treat (2012) 0.93
Behavior therapy for tics in children: acute and long-term effects on psychiatric and psychosocial functioning. J Child Neurol (2011) 0.92
Tourette syndrome increases risk of bone fractures: a population-based cohort study. Eur Child Adolesc Psychiatry (2016) 0.91
The Inheritance of Tourette Disorder: A review. J Obsessive Compuls Relat Disord (2014) 0.91
Treatment of Tourette syndrome. Neurotherapeutics (2014) 0.90
A cluster analysis of tic symptoms in children and adults with Tourette syndrome: clinical correlates and treatment outcome. Psychiatry Res (2013) 0.88
Behavior Therapy for Tic Disorders: An Evidenced-based Review and New Directions for Treatment Research. Curr Dev Disord Rep (2015) 0.86
Pediatric indications for deep brain stimulation. Childs Nerv Syst (2012) 0.85
Tourette syndrome and obsessive-compulsive disorder. Brain Dev (2007) 0.83
Health care needs of children with Tourette syndrome. J Child Neurol (2012) 0.82
Drug and non-drug treatments of children with ADHD and tic disorders. Eur Child Adolesc Psychiatry (2007) 0.82
The Tourette International Collaborative Genetics (TIC Genetics) study, finding the genes causing Tourette syndrome: objectives and methods. Eur Child Adolesc Psychiatry (2014) 0.80
Cognitive behavioral management of Tourette's syndrome and chronic tic disorder in medicated and unmedicated samples. Behav Res Ther (2009) 0.79
Bothersome tics in patients with chronic tic disorders: Characteristics and individualized treatment response to behavior therapy. Behav Res Ther (2015) 0.78
Prefrontal dysfunction in pediatric Tourette's disorder as measured by near-infrared spectroscopy. BMC Psychiatry (2015) 0.77
Intensive outpatient comprehensive behavioral intervention for tics: A case series. World J Clin Cases (2014) 0.77
The pharmacology of Tourette syndrome. J Neural Transm (Vienna) (2013) 0.77
Neuroimaging in Tourette Syndrome: Research Highlights From 2014-2015. Curr Dev Disord Rep (2015) 0.76
Efficacy of Glutamate Modulators in Tic Suppression: A Double-Blind, Randomized Control Trial of D-serine and Riluzole in Tourette Syndrome. Pediatr Neurol (2015) 0.76
Utility of the diagnostic interview schedule for children for assessing Tourette syndrome in children. J Child Adolesc Psychopharmacol (2014) 0.76
Paliperidone extended release for the treatment of pediatric and adolescent patients with Tourette's disorder. Ann Gen Psychiatry (2014) 0.76
Further evidence of behavioral interventions for tic disorders: A reply to Theule and colleagues. J Psychiatr Res (2015) 0.75
Tourette syndrome associated with attention deficit hyperactivity disorder: The impact of tics and psychopharmacological treatment options. World J Clin Pediatr (2016) 0.75
Pediatric psychopharmacology update: psychostimulants and tics - past, present and future. J Can Acad Child Adolesc Psychiatry (2006) 0.75
A case of Gilles de la Tourette's syndrome. Ind Psychiatry J (2016) 0.75
Pediatric neurotherapy. NeuroRx (2012) 0.75
Pediatric Autoimmune Disorders Associated with Streptococcal Infections and Tourette's Syndrome in Preclinical Studies. Front Neurosci (2016) 0.75
Evidence-based pharmacotherapy for pediatric obsessive-compulsive disorder and chronic tic disorders. J Cent Nerv Syst Dis (2011) 0.75
Misplaced Fear? FDA Contraindication to Psychostimulant Use in Children with Tics. Evid Based Child Health (2012) 0.75
The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry (1989) 16.61
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry (1999) 13.56
Risperidone in children with autism and serious behavioral problems. N Engl J Med (2002) 9.35
Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry (1997) 7.10
The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry (1989) 6.98
The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry (1989) 6.80
Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am (2003) 5.05
An international perspective on Tourette syndrome: selected findings from 3,500 individuals in 22 countries. Dev Med Child Neurol (2000) 3.99
Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry (2002) 3.89
Treatment of ADHD in children with tics: a randomized controlled trial. Neurology (2002) 3.63
Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet (1999) 3.11
Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry (1991) 3.02
Normative data on revised Conners Parent and Teacher Rating Scales. J Abnorm Child Psychol (1978) 2.82
Tourette's syndrome. N Engl J Med (2001) 2.78
Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry (1997) 2.68
Regional brain and ventricular volumes in Tourette syndrome. Arch Gen Psychiatry (2001) 2.59
Tourette's syndrome. Lancet (2002) 2.56
Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics (2001) 2.48
A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry (2000) 2.48
Antibodies against human putamen in children with Tourette syndrome. Neurology (1998) 2.43
The use of intravenous chlorimipramine in the treatment of obsessive compulsive disorder. Can J Psychiatry (1984) 2.42
Basal Ganglia volumes in patients with Gilles de la Tourette syndrome. Arch Gen Psychiatry (2003) 2.33
Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA (1998) 2.20
Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry (2001) 2.06
A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry (2001) 1.95
Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics (1990) 1.88
The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res (2004) 1.85
An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (1995) 1.81
Psychosocial treatment strategies in the MTA study: rationale, methods, and critical issues in design and implementation. J Abnorm Child Psychol (2000) 1.81
Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatry (2005) 1.78
Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology (2004) 1.72
Clinical practice. Obsessive-compulsive disorder. N Engl J Med (2004) 1.70
Disruptive behavior in children with Tourette's syndrome: association with ADHD comorbidity, tic severity, and functional impairment. J Am Acad Child Adolesc Psychiatry (2003) 1.69
Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study. J Clin Psychiatry (2001) 1.63
Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology (1997) 1.62
The Leyton obsessional inventory. Psychol Med (1970) 1.62
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry (2002) 1.60
Tourette's syndrome and deep brain stimulation. J Neurol Neurosurg Psychiatry (2005) 1.60
Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry (1996) 1.58
Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry (1994) 1.56
Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry (1995) 1.55
Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry (1999) 1.53
Another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatry (1993) 1.53
Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (1995) 1.52
A placebo-controlled trial of risperidone in Tourette syndrome. Neurology (2003) 1.52
Attention deficit disorder and methylphenidate: normalization rates, clinical effectiveness, and response prediction in 76 children. J Am Acad Child Adolesc Psychiatry (1994) 1.51
Tourette's syndrome: a cross sectional study to examine the PANDAS hypothesis. J Neurol Neurosurg Psychiatry (2003) 1.51
Tics in Tourette syndrome: new treatment options. J Child Neurol (1999) 1.46
Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry (2001) 1.40
Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry (2000) 1.36
Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry (2000) 1.36
Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord (2003) 1.35
Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry (2001) 1.34
Striatal microinfusion of Tourette syndrome and PANDAS sera: failure to induce behavioral changes. Mov Disord (2004) 1.32
Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatry (1997) 1.30
A pilot study of penicillin prophylaxis for neuropsychiatric exacerbations triggered by streptococcal infections. Biol Psychiatry (1999) 1.29
Definitions and classification of tic disorders. The Tourette Syndrome Classification Study Group. Arch Neurol (1993) 1.28
Controlled study of pimozide vs. placebo in Tourette's syndrome. J Am Acad Child Psychiatry (1984) 1.26
Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination? Biol Psychiatry (2002) 1.25
Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry (1996) 1.24
Anxiety disorders and tic severity in juveniles with Tourette's disorder. J Am Acad Child Adolesc Psychiatry (2000) 1.22
Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am J Psychiatry (2002) 1.22
Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. Neurology (2001) 1.22
Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology (2001) 1.22
Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry (1997) 1.19
Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry (2004) 1.19
Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry (2004) 1.16
Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome. Mov Disord (2005) 1.16
Detecting pediatric autoimmune neuropsychiatric disorders associated with streptococcus in children with obsessive-compulsive disorder and tics. Biol Psychiatry (2004) 1.16
Habit reversal versus supportive psychotherapy for Tourette's disorder: a randomized controlled trial. Am J Psychiatry (2003) 1.15
Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res (1991) 1.15
Surgery in Tourette syndrome. Mov Disord (2004) 1.14
Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry (2002) 1.14
Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol (2002) 1.12
Explosive outbursts in children with Tourette's disorder. J Am Acad Child Adolesc Psychiatry (2000) 1.10
A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry (1989) 1.10
Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry (1989) 1.09
"Just right" perceptions associated with compulsive behavior in Tourette's syndrome. Am J Psychiatry (1994) 1.09
Treating generalized anxiety disorder. J Clin Psychiatry (2003) 1.06
Treatment of obsessive-compulsive disorder. The Expert Consensus Panel for obsessive-compulsive disorder. J Clin Psychiatry (1997) 1.06
Anti-striatal antibodies in Tourette syndrome cause neuronal dysfunction. J Neuroimmunol (2000) 1.05
Antibodies against neural, nuclear, cytoskeletal, and streptococcal epitopes in children and adults with Tourette's syndrome, Sydenham's chorea, and autoimmune disorders. Biol Psychiatry (2001) 1.04
An animal model of Tourette's syndrome. Am J Psychiatry (2002) 1.04
Behavioral and emotional aspects of Tourette syndrome. Neurol Clin (1997) 1.04
A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila) (2000) 1.04
Refractory obsessive-compulsive disorder: state-of-the-art treatment. J Clin Psychiatry (2002) 1.03
Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. Arch Pediatr Adolesc Med (1994) 1.03
A controlled study of Tourette syndrome. V. Depression and mania. Am J Hum Genet (1987) 1.03
Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology (1988) 1.01
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J Clin Psychiatry (2001) 1.00
A double-blind trial of bupropion in children with attention deficit disorder. Psychopharmacol Bull (1987) 1.00
Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. A double-blind crossover comparison. Arch Gen Psychiatry (1989) 0.99
Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry (2004) 0.99
Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette's disorder. Am J Psychiatry (1988) 0.99
The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry (1979) 0.98
Clonidine in Tourette's syndrome. Lancet (1979) 0.98
Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine. Depress Anxiety (2002) 0.98
The Leyton Obsessional Inventory-Child Version. J Am Acad Child Psychiatry (1986) 0.98
A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome. Am J Psychiatry (1978) 0.97
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science (2005) 8.20
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med (2009) 5.81
Levodopa and the progression of Parkinson's disease. N Engl J Med (2004) 5.44
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Effect of honey, dextromethorphan, and no treatment on nocturnal cough and sleep quality for coughing children and their parents. Arch Pediatr Adolesc Med (2007) 4.81
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol (2002) 4.60
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Effect of dextromethorphan, diphenhydramine, and placebo on nocturnal cough and sleep quality for coughing children and their parents. Pediatrics (2004) 3.25
L-histidine decarboxylase and Tourette's syndrome. N Engl J Med (2010) 2.92
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol (2003) 2.81
Movement disorders in cerebrovascular disease. Lancet Neurol (2013) 2.81
Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord (2006) 2.72
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol (2012) 2.50
Treatment for Adolescents with Depression Study (TADS): safety results. J Am Acad Child Adolesc Psychiatry (2006) 2.45
Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology (2013) 2.45
A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology (2004) 2.35
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord (2007) 2.34
The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain (2008) 2.34
Basal Ganglia volumes in patients with Gilles de la Tourette syndrome. Arch Gen Psychiatry (2003) 2.33
Rare copy number variants in tourette syndrome disrupt genes in histaminergic pathways and overlap with autism. Biol Psychiatry (2011) 2.28
Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet (2002) 2.27
Camptocormia: pathogenesis, classification, and response to therapy. Neurology (2005) 2.26
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18
Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep (2011) 2.17
The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms. Mov Disord (2011) 2.16
Are Parkinson disease patients protected from some but not all cancers? Neurology (2007) 2.12
Vapor rub, petrolatum, and no treatment for children with nocturnal cough and cold symptoms. Pediatrics (2010) 2.09
The human immune response to streptococcal extracellular antigens: clinical, diagnostic, and potential pathogenetic implications. Clin Infect Dis (2010) 2.04
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg (2006) 2.02
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Hair apparent: Rapunzel syndrome. Am J Psychiatry (2005) 1.98
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet (2003) 1.98
Recovery and recurrence following treatment for adolescent major depression. Arch Gen Psychiatry (2010) 1.89
Genetics of essential tremor. Brain (2007) 1.89
Update on blepharospasm: report from the BEBRF International Workshop. Neurology (2008) 1.87
Pediatric autoimmune neuropsychiatric disorders associated with streptococcus: comparison of diagnosis and treatment in the community and at a specialty clinic. Pediatrics (2008) 1.85
The heart of the matter on breastmilk and environmental chemicals: essential points for healthcare providers and new parents. Breastfeed Med (2008) 1.85
Tourette syndrome: evolving concepts. Mov Disord (2011) 1.84
Overrepresentation of rare variants in a specific ethnic group may confuse interpretation of association analyses. Hum Mol Genet (2006) 1.84
Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord (2006) 1.82
Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord (2010) 1.76
Development of the Hypertonia Assessment Tool (HAT): a discriminative tool for hypertonia in children. Dev Med Child Neurol (2010) 1.76
Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist (2008) 1.74
Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location. J Neurol Sci (2009) 1.73
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord (2010) 1.71
Disruptive behavior in children with Tourette's syndrome: association with ADHD comorbidity, tic severity, and functional impairment. J Am Acad Child Adolesc Psychiatry (2003) 1.69
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68
Tourette syndrome: the self under siege. J Child Neurol (2006) 1.67
Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain. Neurology (2008) 1.66
Premutation alleles associated with Parkinson disease and essential tremor. JAMA (2004) 1.65
Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem Biophys Res Commun (2005) 1.64
Clinical gait and balance scale (GABS): validation and utilization. J Neurol Sci (2004) 1.62
Migraine headache in patients with Tourette syndrome. Arch Neurol (2003) 1.61
Minocycline in Huntington's disease: a pilot study. Mov Disord (2004) 1.59
Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat (2010) 1.57
Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol (2009) 1.56
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord (2008) 1.56
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord (2005) 1.54
Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol (2005) 1.54
Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin Neuropharmacol (2003) 1.53
Camptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of Parkinsonian deformities. Mov Disord (2010) 1.52
Dose-response relationship with increasing doses of dextromethorphan for children with cough. Clin Ther (2004) 1.52
Secondary tics and tourettism. Rev Bras Psiquiatr (2005) 1.47
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci (2011) 1.46
Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis (2008) 1.43
Atomoxetine and tics in ADHD. J Am Acad Child Adolesc Psychiatry (2004) 1.43
Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett (2010) 1.42
Alternative modified infant-feeding practices to prevent postnatal transmission of human immunodeficiency virus type 1 through breast milk: past, present, and future. J Hum Lact (2006) 1.41
Children and adolescents with Tourette's disorder in the USA versus Argentina: behavioral differences may reflect cultural factors. Eur Child Adolesc Psychiatry (2013) 1.40
Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry (2006) 1.38
Declining medication requirement in some patients with advanced Parkinson disease and dementia. Clin Neuropharmacol (2003) 1.38
LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics (2010) 1.37
The safety and efficacy of thalamic deep brain stimulation in essential tremor: 10 years and beyond. J Neurol Neurosurg Psychiatry (2013) 1.36
Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord (2003) 1.35
Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry (2004) 1.34
Tourette syndrome and tic disorders: a decade of progress. J Am Acad Child Adolesc Psychiatry (2007) 1.33
Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin (2004) 1.33
Scientific and ethical issues related to deep brain stimulation for disorders of mood, behavior, and thought. Arch Gen Psychiatry (2009) 1.33
Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord (2007) 1.32
Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord (2010) 1.31